10-QPeriod: Q3 FY2005

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2005

Filed November 14, 2005For Securities:ALNY

Summary

This 10-Q filing from Alnylam Pharmaceuticals, Inc. (ALNY) for the period ending September 30, 2005, provides investors with a look into the company's financial standing and operational performance during the third quarter and the first nine months of the year. As a clinical-stage biopharmaceutical company, Alnylam's financial results are primarily characterized by significant research and development expenses, which are typical for companies in this sector investing heavily in pipeline advancement. Investors should focus on the company's cash burn rate, its ability to fund ongoing operations through its existing cash and equivalents, and the progress of its key drug candidates, which are not detailed in this specific filing but are the drivers of future revenue potential. The filing includes unaudited interim consolidated financial statements, including balance sheets, statements of operations, and cash flows. Management's Discussion and Analysis (MD&A) section offers insights into the company's financial condition and results of operations, crucial for understanding the drivers behind the reported numbers. While specific revenue figures and profitability are likely not yet substantial given the company's stage, the focus remains on the strategic execution of its research and development strategy and its financial runway to achieve its development milestones.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2005.
  • 2The filing includes unaudited interim consolidated financial statements: Balance Sheets, Statements of Operations, and Cash Flows.
  • 3Management's Discussion and Analysis (MD&A) provides operational and financial insights.
  • 4As a clinical-stage biopharmaceutical company, significant R&D expenses are expected, impacting net loss.
  • 5Focus for investors is on cash position, burn rate, and pipeline development progress, information typically found in the MD&A.
  • 6No revenue generation from product sales is anticipated at this early stage of development.

Frequently Asked Questions

The unaudited interim consolidated balance sheets provide the snapshot of Alnylam's financial position. Investors should review the reported cash and cash equivalents, total assets, liabilities, and the overall equity position to understand the company's financial health at that time.

The unaudited interim consolidated statements of operations show the company's revenue (if any), research and development expenses, general and administrative expenses, and the resulting net loss for the three and nine months ended September 30, 2005, compared to the prior year. This helps in understanding the operational trends and investment in R&D.

While not detailed in the provided snippet, the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section is where the company would typically discuss key risks, such as the inherent uncertainties in drug development, regulatory approvals, competition, and financing needs.

The statements of cash flows for the nine months ended September 30, 2005, will detail the sources and uses of cash, including operating activities (likely resulting in cash outflows due to R&D), investing activities, and financing activities (such as equity raises). This provides insight into how the company is managing its cash burn and runway.